Abstract
Several disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, however, has not been evaluated for its effects on cognition in detail so far. To explore the influence of alemtuzumab on cognitive impairment in active relapsing-remitting MS (RRMS) as well as possible clinical and neuroimaging predictors of cognitive changes during the first year of therapy. Extensive neuropsychological assessment was administered to 21 patients with active RRMS at baseline and again after the second treatment with alemtuzumab (mean time span: 15.05 months). Clinical and routine structural neuroimaging markers were explored for their capacity to predict individual courses of cognitive change. Overall cognitive functioning remained stable or improved during the observational period of alemtuzumab treatment on average. Scores on two neuropsychological tests of processing speed significantly improved and clinically relevant individual gains of processing speed were seen in the majority of patients. Linear regression models showed that clinical and routine neuroimaging measures of disease activity could not fully account for these cognitive changes. Results suggest that alemtuzumab treatment in active RRMS stabilizes overall cognitive functioning and furthermore positively affects cognitive processing speed. Changes in processing speed were independent from clinical and structural neuroimaging parameters of disease activity and may thus represent an underrated and independent outcome measure to evaluate treatment effects.
Highlights
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, often affecting young adults [1]
The present study provides a comprehensive and systematic analysis of the early changes in cognition following alemtuzumab treatment in active relapsing–remitting MS (RRMS)
Our findings provide further evidence that highly potent Disease-modifying drugs (DMDs) can stabilize and possibly even reduce cognitive impairment in active RRMS
Summary
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, often affecting young adults [1]. Regarding first-line treatments, interferon beta1a has shown promising effects on processing speed and other cognitive domains [10,11,12]. In line with their stronger effect on conventional clinical and paraclinical outcome measures, monoclonal antibody treatments (e.g., natalizumab and daclizumabHYP) may even surpass first-line treatments regarding positive effects on cognition, processing speed [13,14,15,16]. Several disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, has not been evaluated for its effects on cognition in detail so far
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
